Ocugen Inc Stock Price, News & Analysis

Ocugen, a biotechnology company, announces its in-person Research & Development (R&D) Day on November 1, 2022, at the Nasdaq Market Site in New York City. The event aims to showcase Ocugen's innovative gene therapy and vaccine technologies, with panel discussions featuring leading experts such as Neena B. Haider, Mark Pennesi, and David Fajgenbaum. Attendees will gain insights into Ocugen's pipeline and business strategies. Registration is required, and a webcast replay will be available within 48 hours post-event.

Ocugen, Inc. (NASDAQ: OCGN) announced that the Independent Data and Safety Monitoring Board completed a review of the safety data for its OCU400 Phase 1/2 clinical trial and recommends proceeding to enroll subjects in Cohort 3. No safety concerns were noted in the ongoing trial, which focuses on treating inherited retinal degeneration. The company expects to complete Cohort 3 enrollment by Q4 2022. OCU400 aims to address unmet needs in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations.

Ocugen, a biotechnology firm (NASDAQ: OCGN), announced participation in two key conferences on October 12, 2022. Dr. Shankar Musunuri will present their Modifier Gene Therapy platform for inherited retinal diseases at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, CA, while Dr. Robert J. Hopkins will discuss COVAXIN™, a COVID-19 vaccine candidate in Phase 2/3 trials, at the Vaccines Summit in Reston, VA. The company emphasizes its commitment to innovative gene and cell therapies aimed at improving global health.

Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri, CEO and Co-Founder, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 4, 2022. The event takes place at the Westin Grand Central Hotel in New York City, from 8:30 to 8:55 a.m. ET. A live webcast will be available for viewers. Ocugen focuses on developing innovative gene and cell therapies, aiming to improve health and address unmet medical needs globally. For more details, visit their website.

Ocugen announced on Sept. 16, 2022, that its Compensation Committee approved stock options and restricted stock units (RSUs) for five new hires, totaling 148,800 shares in stock options and 40,092 shares in RSUs. The options, granted at an exercise price of $2.17, have a ten-year term and vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. Ocugen focuses on novel gene and cell therapies and vaccines, aiming to improve health and address unmet medical needs.

Ocugen, Inc. announced the publication of a comprehensive review on BBV152, commercialized as COVAXIN™, highlighting its effectiveness against COVID-19 and its variants, particularly Delta and Omicron. The review published in Frontiers in Immunology emphasizes the vaccine's immunogenicity, safety, and efficacy. BBV152 shows 77.8% protection from symptomatic COVID-19 and over 95% seroconversion in pediatric populations. COVAXIN™ has been authorized in 28 countries and accepted by over 85 for travel, enhancing its global accessibility. The company is investigating its use in adults in the U.S.

Ocugen, a biotechnology company, announces that Chief Scientific Officer Arun Upadhyay will speak at the 3rd Annual Gene Therapy for Ophthalmic Disorders Conference from September 13-16 in Danvers, Massachusetts. Dr. Upadhyay's presentation, scheduled for September 14 at 9:15 a.m. ET, will focus on the Modifier Gene Therapy Approach for Retinitis Pigmentosa. This event highlights Ocugen's commitment to advancing innovative therapies for retinal diseases. The company is actively developing gene and cell therapies to improve patient outcomes globally.

Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. The chat is scheduled for September 12, 2022, from 3:30 – 4:00 p.m. ET at the Lotte New York Palace Hotel. A live video webcast will be available on the Ocugen investor site at the time of the event, with a replay archived for 90 days. Ocugen focuses on innovative gene and cell therapies and vaccines.